ALR Target Identification in Lupus -
2009 Grantees

In 2009, the ALR is committing funding to 10 Target Identification in Lupus (TIL) grants: 8 new research grants and 2 renewed grants. Most TIL investigators are receiving research grants of approximately $500,000 over two years. The ALR is also proud to provide ongoing support for researchers in their second year of TIL funding and for additional, extended TIL projects.

Below is a list of 2009 Grantees:

Harini Bagavant, MD, PhD
University of Virginia
Modulating Renal Responses: A Novel Therapeutic Approach in Lupus Nephritis

Nina Bhardwaj, MD, PhD
NYU School of Medicine
Inducing Tolerance in SLE Through Modulation of Apoptotic Cell Receptors

Sergei Kotenko, PhD
New Jersey Medical School
Inhibition of Type I and Type III IFNs by Poxvirus-Encoded Soluble Proteins

Mark Mamula, PhD
Yale University
Antigen Trafficking Between APCs as Therapeutic Target for Lupus

Laurence Morel, PhD
University of Florida
Retinoic Acid Regulation of T Cell Homeostasis in Lupus

James Oates, MD
Medical University of South Carolina
The Role of Sphingosine Kinase in Systemic Lupus Erythematosus

Derry Roopenian, PhD
The Jackson Laboratory
Function Dissection of Interleukin-21 in Lupus

Marie-Laure Santiago-Raber, PhD
Centre Medical Universitaire (Switzerland)
Selective Blocking of Plasma-Cell Survival Factor APRIL in SLE

Alessandra Pernis, MD - Renewal
Columbia University Medical Center
Role of Rho GTPases and their Activators in Lupus Pathogenesis

Lars Ronnblom, MD, PhD - Renewal
Uppsala University (Sweden)
Functional Consequences of Type I IFN System Gene Variants in SLE

2008 TIL Grantees